EUVIMEDEUVIMED entdecken
Open Access

Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review)

Xiao Hu, Jin Ren, Qianfei Xue, Rumei Luan, Dongyan Ding, Jie Tan, Xin Su, Junling Yang

International Journal of Oncology · 2023

DOI: 10.3892/ijo.2023.5570 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Oncology, 2023. Verfasst von Xiao Hu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pneumonia. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) play a significant anti‑tumor role in the management of non‑small cell lung cancer. The most broadly used ICIs are anti‑programmed death 1 (PD‑1), anti‑programmed cell death‑ligand 1, and anti‑cytotoxic T lymphocyte‑associated antigen‑4 monoclonal antibody. Compared with traditional chemotherapy, ICIs have the advantages of greater efficiency and more specific targeting. However, the resulting immune‑related adverse events limit the clinical application of ICIs, especially checkpoint inhibitor pneumonitis (CIP). CIP chiefly occurs within 6 months of administration of ICIs. Excessive activation and amplification of cytotoxic T lymphocytes, helper T cells, downregulation of regulatory T cells, and over‑secretion of pro‑inflammatory cytokines are the dominant mechanisms underlying the pathophysiology of CIP. The dysregulation of innate immune cells, such as an increase in inflammatory monocytes, dendritic cells, neutrophils and M1 polarization of macrophages, an increase in IL‑10 and IL‑35, and a decrease in eosinophils, may underlie CIP. Although contested, several factors may accelerate CIP, such as a history of previous respiratory disease, radiotherapy, chemotherapy, administration of epidermal growth factor receptor tyrosine kinase inhibitors, PD‑1 blockers, first‑line application of ICIs, and combined immunotherapy. Interestingly, first‑line ICIs plus chemotherapy may reduce CIP. Steroid hormones remain the primary treatment strategy against grade ≥2 CIP, although cytokine blockers are promising therapeutic agents. Herein, the current research on CIP occurrence, clinical and radiological characteristics, pathogenesis, risk factors, and management is summarized to further expand our understanding, clarify the prognosis, and guide treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsPneumoniaHumansImmune Checkpoint InhibitorsB7-H1 AntigenRisk FactorsCytokines

Stichwörter der Autor:innen

checkpoint inhibitor pneumonitisimmune checkpoint inhibitorsoccurrencepathogenesisrisk factors

Substanzen

Immune Checkpoint InhibitorsCD274 protein, humanB7-H1 AntigenCytokines

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China.
  • Department of Respiratory Medicine, Hospital of Jilin University, Changchun, Jilin 130012, P.R. China.

Zitieren

APA

Hu, X., Ren, J., Xue, Q., Luan, R., Ding, D., Tan, J., Su, X., & Yang, J. (2023). Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review). International Journal of Oncology. https://doi.org/10.3892/ijo.2023.5570

Vancouver

Hu X, Ren J, Xue Q, Luan R, Ding D, Tan J, et al. Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review). International Journal of Oncology. 2023. doi:10.3892/ijo.2023.5570

BibTeX
@article{Hu2023,
  author = {Hu, Xiao and Ren, Jin and Xue, Qianfei and Luan, Rumei and Ding, Dongyan and Tan, Jie and Su, Xin and Yang, Junling},
  title = {Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review)},
  journal = {International Journal of Oncology},
  year = {2023},
  doi = {10.3892/ijo.2023.5570}
}
Kostenlos starten →